Frovatriptan: Difference between revisions

Revision as of 16:02, 7 February 2014

Frovatriptan
FROVA^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Frovatriptan
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

For patient information about Frovatriptan, click here

Synonyms / Brand Names: FROVA^®

Overview

Frovatriptan (trade name Frova) is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. The product is licensed to Endo Pharmaceuticals in North America andMenarini in Europe.^[1]

FDA Package Insert

Mechanism of Action

References

↑ "Frova". Vernalis. Retrieved 2007-11-28.

Template:WikiDoc Sources

[1] "Frova". Vernalis. Retrieved 2007-11-28.

[1]

@@ Line 1: / Line 1: @@
-<!-- FAIR USE of Frovatriptan_Frova.gif: see image description page at http://en.wikipedia.org/wiki/Image:Frovatriptan_Frova.gif for rationale -->
+__NOTOC__
-{{drugbox |
-|image=Frovatriptan.svg
-|image2=Frovatriptan_Frova.gif
-|IUPAC_name =6-methylamino-6,7,8,9-tetrahydro-<br>5''H''-carbazole-3-carboxamide
-|CAS_number =158930-17-7
-|ATC_code =N02CC07
-|ATC_prefix=N02
-|ATC_suffix=CC07
-|PubChem=5284561
-|DrugBank=APRD00270
-| C=14 | H=17 | N=3 | O=1
-|molecular_weight =243.304 [[gram|g]]/[[mole (unit)|mol]]
-|bioavailability =20-30%
-|metabolism =[[Liver|Hepatic]]
-|elimination_half-life =26 [[hour]]s
-|excretion =[[Kidney|Renal]]
-|pregnancy_category =C: ([[United States|USA]])<br>B3: ([[Australia|AUS]])
-|legal_status = [[Prescription drug|Prescription only]]
-|routes_of_administration =[[Mouth|Oral]]
-}}
-'''Frovatriptan''' (trade name '''Frova''') is a [[triptan]] [[medication|drug]] developed by [[Vernalis]] for the treatment of [[migraine]] [[headache]]s, in particular those associated with [[menstruation]].  The product is licensed to [[Endo Pharmaceuticals]] in North America and [[Menarini]] in Europe.<ref>{{cite web |title=Frova |url=http://www.vernalis.com/ver/rdc2/pain/frovatriptan/ |publisher=Vernalis |accessdate=2007-11-28}}</ref>
+{{Frovatriptan}}
-==Pharmacology==
+{{CMG}}; {{AE}} {{SS}}
-Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. It is available as 2.5&nbsp;mg tablets.
-Frovatriptan has mean terminal elimination [[half-life]] of approximately 26 hours, which is substantially longer than other triptans.
+'''''For patient information about Frovatriptan, click [[Frovatriptan (patient information)|here]]'''''
-==US licensing==
+{{SB}} FROVA<sup>®</sup>
-Frovatriptan is available only by [[Medical prescription|prescription]] in the [[United States]], where a secondary New Drug Approval (sNDA) was filed in July 2006,<ref>{{cite web |title=Patient Information Sheet -- Frovatriptan succinate (marketed as Frova) |url=http://www.fda.gov/cder/drug/InfoSheets/patient/frovatripanPIS.htm |date=07/2006 |publisher=Food and Drug Administration |accessdate=2007-11-28}}</ref> and which is currently pending. The FDA anticipates completing its review of this application on or before the current PDUFA (Prescription Drug User Fee Act) review date of August 19, 2007.  If the sNDA is approved, Frova will be the only medication indicated in the U.S. for the short-term prevention of menstrual migraine (MM).
-==Footnotes==
+==Overview==
-{{reflist|2}}
-== External links ==
+'''Frovatriptan''' (trade name '''Frova''') is a [[triptan]] [[medication|drug]] developed by [[Vernalis]] for the treatment of [[migraine]][[headache]]s, in particular those associated with [[menstruation]].  The product is licensed to [[Endo Pharmaceuticals]] in North America and[[Menarini]] in Europe.<ref>{{cite web |title=Frova |url=http://www.vernalis.com/ver/rdc2/pain/frovatriptan/ |publisher=Vernalis |accessdate=2007-11-28}}</ref>
-* [http://www.frova.com/ Frova] (manufacturer's website)
+==Category==
-* [http://www.healthsquare.com/newrx/fro1622.htm/ Frovatriptan Succinate]  (patient information)
-{{triptans}}
+==FDA Package Insert==
+'''| [[Frovatriptan indications and usage|Indications and Usage]]'''
+'''| [[Frovatriptan dosage and administration|Dosage and Administration]]'''
+'''| [[Frovatriptan dosage forms and strengths|Dosage Forms and Strengths]]'''
+'''| [[Frovatriptan contraindications|Contraindications]]'''
+'''| [[Frovatriptan warnings and precautions|Warnings and Precautions]]'''
+'''| [[Frovatriptan adverse reactions|Adverse Reactions]]'''
+'''| [[Frovatriptan drug interactions|Drug Interactions]]'''
+'''| [[Frovatriptan use in specific populations|Use in Specific Populations]]'''
+'''| [[Frovatriptan overdosage|Overdosage]]'''
+'''| [[Frovatriptan description|Description]]'''
+'''| [[Frovatriptan clinical pharmacology|Clinical Pharmacology]]'''
+'''| [[Frovatriptan nonclinical toxicology|Nonclinical Toxicology]]'''
+'''| [[Frovatriptan clinical studies|Clinical Studies]]'''
+'''| [[Frovatriptan how supplied storage and handling|How Supplied/Storage and Handling]]'''
+'''| [[Frovatriptan patient counseling information|Patient Counseling Information]]'''
+'''| [[Frovatriptan labels and packages|Labels and Packages]]'''
+==Mechanism of Action==
+==References==
+{{Reflist|2}}
 [[Category:Triptans]]
+[[Category:Cardiovascular Drugs]]
+[[Category:Drugs]]
-{{pharma-stub}}
+{{WikiDoc Help Menu}}
-[[de:Frovatriptan]]
+{{WikiDoc Sources}}